Last reviewed · How we verify
Homologous mRNA booster vaccine
Homologous mRNA booster vaccine is a mRNA vaccine Biologic drug developed by Tan Tock Seng Hospital. It is currently FDA-approved for COVID-19 booster vaccination in previously vaccinated individuals.
A homologous mRNA booster vaccine that encodes viral antigens to enhance and broaden immune responses in individuals previously vaccinated against COVID-19.
A homologous mRNA booster vaccine that encodes viral antigens to enhance and broaden immune responses in individuals previously vaccinated against COVID-19. Used for COVID-19 booster vaccination in previously vaccinated individuals.
At a glance
| Generic name | Homologous mRNA booster vaccine |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Drug class | mRNA vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This vaccine uses messenger RNA technology to express viral spike protein or related antigens, designed to boost and diversify the T-cell and B-cell responses elicited by primary COVID-19 vaccination. By using a homologous (same-platform) mRNA approach, it aims to reinvigorate waning immunity and improve protection against emerging variants through repeated antigenic stimulation.
Approved indications
- COVID-19 booster vaccination in previously vaccinated individuals
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers (PHASE1)
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PHASE4)
- Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile (PHASE2)
- Adaptive Immune Response to COVID-19 Vaccination
- A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster (PHASE1)
- COVID-19 Booster Vaccination in Persons With Multiple Sclerosis (EARLY_PHASE1)
- Serology After BBIBP-CorV Inactivated Vaccine Combined With BNT62b2 mRNA Booster Vaccine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Homologous mRNA booster vaccine CI brief — competitive landscape report
- Homologous mRNA booster vaccine updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI
Frequently asked questions about Homologous mRNA booster vaccine
What is Homologous mRNA booster vaccine?
How does Homologous mRNA booster vaccine work?
What is Homologous mRNA booster vaccine used for?
Who makes Homologous mRNA booster vaccine?
What drug class is Homologous mRNA booster vaccine in?
What development phase is Homologous mRNA booster vaccine in?
What are the side effects of Homologous mRNA booster vaccine?
Related
- Drug class: All mRNA vaccine drugs
- Manufacturer: Tan Tock Seng Hospital — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 booster vaccination in previously vaccinated individuals
- Compare: Homologous mRNA booster vaccine vs similar drugs
- Pricing: Homologous mRNA booster vaccine cost, discount & access